Protocol summary
-
Study aim
-
Objective: evaluating the effect of total anthocyanin base standardized (cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde and adiponectin in patients with non-alcoholic fatty liver (NAFLD).
-
Design
-
Patients are randomly assigned into 2 groups (n=40 in each group) using a software to receive total anthocyanin base standardized (cornus mas L.) fruit extract (equal to 320 mg/d anthocyanins) or placebo daily for 12 weeks.
-
Settings and conduct
-
In a randomized double-blind clinical trial, 80 patients with NAFLD will be recruited from Diabetes Research Center, Shahid Sadoughi university of medical sciences, Yazd. The subjects are randomly divided into two groups to take total anthocyanin base standardized (cornus mas L.) fruit extract or placebo.
-
Participants/Inclusion and exclusion criteria
-
Study population: patients with NAFLD (n=80).
Inclusion criteria: ALT levels more than 30 U / L in men and more than 19 U / L in women, age 25-26 years, the patients with grade 1, 2 and 3 fatty liver, the consent of subject to participate in the study, the patients are from Yazd.
Exclusion criteria: The history of diseases including cirrhosis, viral hepatitis, cardiovascular disease, diabetes, Wilson and cancer; Consumption of medications including corticosteroids, nonsteroidal anti-inflammatory drugs, hypoglycemic agents, tamoxifen, sodium valproate, methotrexate, probiotics, any medicine or supplement that affect liver function, supplements with antioxidant and anti-inflammatory properties; Following a special diet; Pregnancy and breastfeeding; Alcohol consumption.
-
Intervention groups
-
Intervention group with total anthocyanin base standardized (cornus mas L.) fruit extract or placebo group.
-
Main outcome variables
-
Liver function (liver enzymes and cytokeratin-18 levels, liver steatosis and fibrosis); tumor necrosis factor α, malondealdehyde and adiponectin levels.
General information
-
Reason for update
-
A secondary outcome was modified without changing other sections of the protocol.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20180419039359N1
Registration date:
2018-09-30, 1397/07/08
Registration timing:
prospective
Last update:
2021-11-23, 1400/09/02
Update count:
2
-
Registration date
-
2018-09-30, 1397/07/08
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2018-12-22, 1397/10/01
-
Expected recruitment end date
-
2019-06-22, 1398/04/01
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
The study of effect of total anthocyanin base standardized (cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde and adiponectin in patients with non-alcoholic fatty liver.
-
Public title
-
The study of effect of total anthocyanin base standardized (cornus mas L.) fruit extract in patients with non-alcoholic fatty liver
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
ALT levels more than 30 U / L in men and more than 19 U / L in women
Age 25-26 years
Diagnosis of the disease by ultrasonography and by a gastroenterologist
The patients with grade 1, 2 and 3 fatty liver
The consent of subject to participate in the study
The patients are from Yazd
Exclusion criteria:
The history of diseases including cirrhosis, viral hepatitis, cardiovascular disease, diabetes, Wilson and cancer.
Consumption of medications including corticosteroids, nonsteroidal anti-inflammatory drugs, hypoglycemic agents or any medicine that affect blood glucose, tamoxifen, sodium valproate, methotrexate, probiotics, any medicine or supplement that affect liver function, supplements with antioxidant and anti-inflammatory properties (such as vitamin D, vitamin E, omega-3, resveratrol) during 1 month before the study
Following a special diet during 1 month before the study
Pregnancy and breastfeeding
شlcohol consumption
-
Age
-
From 25 years old to 65 years old
-
Gender
-
Both
-
Phase
-
3
-
Groups that have been masked
-
-
Sample size
-
Target sample size:
80
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Randomization is performed using Random allocation software. Also, randomization is stratified by age gender.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
The products ((cornus mas L.) fruit extract and placebo) are packed in the bottles that are same in terms of color, shape and size and labeled with "A" and "B" by an outside person who dose not know the details of the study. Therefore, participants and researchers will not be aware of the nature of the products in bottles.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2018-03-17, 1396/12/26
-
Ethics committee reference number
-
IR.SSU.SPH.REC.1396.171
2
-
Ethics committee
-
-
Approval date
-
2021-05-03, 1400/02/13
-
Ethics committee reference number
-
IR.SSU.SPH.REC.1400.020
Health conditions studied
1
-
Description of health condition studied
-
non-alcoholic fatty liver
-
ICD-10 code
-
K76.0
-
ICD-10 code description
-
Fatty (change of) liver, not elsewhere classified
Primary outcomes
1
-
Description
-
Serum levels of Alanine Aminotransferase (ALT)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
2
-
Description
-
Serum levels of Aspartate Aminotransaminase (AST)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
3
-
Description
-
Serum levels of Tumor necrosis factor α (TNF-α)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA kit
4
-
Description
-
Serum levels of Malondealdehyde (MDA)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA kit
5
-
Description
-
Serum levels of adiponectin
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA kit
6
-
Description
-
Serum levels of cytokeratin-18 fragment M30 (CK-18 M30)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA kit
7
-
Description
-
Liver steatosis
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ultrasonography
8
-
Description
-
Liver fibrosis
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By fibroscan
Secondary outcomes
1
-
Description
-
Fasting blood glucose (FBS)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
2
-
Description
-
Serum levels of Triglyceride (TG)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
3
-
Description
-
Serum levels of High-density lipoprotein (HDL)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
4
-
Description
-
Serum levels of Low-density lipoprotein (LDL)
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
5
-
Description
-
Serum levels of total cholesterol
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
6
-
Description
-
Serum levels of insulin
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA kit
7
-
Description
-
Insulin resistance
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By HOMA-IR and QUICKI
8
-
Description
-
Lipid accumulation product
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
9
-
Description
-
Atherogenic index of plasma
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
10
-
Description
-
Atherogenic coefficient
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
11
-
Description
-
Castelli 1 index
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
12
-
Description
-
Castelli 2 index
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
13
-
Description
-
TyG index
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
14
-
Description
-
Fatty liver index
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
15
-
Description
-
Hepatic steatosis index
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
16
-
Description
-
Visceral adiposity index
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
17
-
Description
-
NAFLD-liver fat score
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
18
-
Description
-
estimated glucose infusion rate
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
Formula
19
-
Description
-
Gamma glutamyl transpeptidase
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By autoanalyzer
20
-
Description
-
Serum levels of E-selectin
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA method
21
-
Description
-
Serum levels of Asymmetric dimethylarginine
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA method
22
-
Description
-
Serum levels of nitric oxide
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA method
23
-
Description
-
Seum levels of C reactive protein
-
Timepoint
-
Before and after the 12-week intervention
-
Method of measurement
-
By ELISA method
Intervention groups
1
-
Description
-
Intervention group: Daily intake of total anthocyanin base standardized (cornus mas L.) fruit extract (equal to 320 mg/d anthocyanins) for 12 weeks.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Daily intake of placebo for 12 weeks.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Yazd University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available